| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $58,383 | 1 | 11 |
Sells | $490,523 | 8 | 89 |
| Leo Chandra P. | director | 1 | $58,383 | 0 | $0 | $58,383 |
| Dunn Edmund | Principal Accounting Officer | 0 | $0 | 2 | $24,936 | $-24,936 |
| Champoux Jennifer | Chief Operating Officer | 0 | $0 | 1 | $39,882 | $-39,882 |
| Janku Filip | Chief Medical Officer | 0 | $0 | 1 | $47,861 | $-47,861 |
| Nickson Philip | Chief Business & Legal Officer | 0 | $0 | 1 | $47,861 | $-47,861 |
| Townson Sharon | Chief Scientific Officer | 0 | $0 | 1 | $47,861 | $-47,861 |
| Warmuth Markus | President & CEO | 0 | $0 | 2 | $282,121 | $-282,121 |
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Over the last 12 months, insiders at Monte Rosa Therapeutics, Inc. have bought $58,383 and sold $490,523 worth of Monte Rosa Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Monte Rosa Therapeutics, Inc. have bought $138.4M and sold $6.4M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Leo Chandra P. (director) — $58,383.
The last purchase of 10,000 shares for transaction amount of $58,383 was made by Leo Chandra P. (director) on 2025‑03‑24.
| 2026-01-07 | Sale | Warmuth Markus | President & CEO | 5,466 0.0082% | $23.49 | $128,373 | +3.35% | |
| 2026-01-05 | Sale | Warmuth Markus | President & CEO | 10,135 0.0154% | $15.17 | $153,748 | +66.60% | |
| 2026-01-05 | Sale | Janku Filip | Chief Medical Officer | 3,155 0.0048% | $15.17 | $47,861 | +66.60% | |
| 2026-01-05 | Sale | Townson Sharon | Chief Scientific Officer | 3,155 0.0048% | $15.17 | $47,861 | +66.60% | |
| 2026-01-05 | Sale | Champoux Jennifer | Chief Operating Officer | 2,629 0.004% | $15.17 | $39,882 | +66.60% | |
| 2026-01-05 | Sale | Nickson Philip | Chief Business & Legal Officer | 3,155 0.0048% | $15.17 | $47,861 | +66.60% | |
| 2026-01-05 | Sale | Dunn Edmund | Principal Accounting Officer | 1,039 0.0016% | $15.17 | $15,762 | +66.60% | |
| 2025-06-03 | Sale | Dunn Edmund | Principal Accounting Officer | 2,062 0.0032% | $4.45 | $9,174 | +49.35% | |
| 2025-03-24 | Leo Chandra P. | director | 10,000 0.0163% | $5.84 | $58,383 | -9.78% | ||
| 2024-10-29 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 67,905 0.1081% | $9.16 | $621,801 | -39.11% | |
| 2024-10-28 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 89,990 0.2667% | $9.66 | $869,240 | -39.82% | |
| 2024-09-20 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 1.13M 1.8595% | $6.53 | $7.4M | -16.82% | |
| 2024-09-13 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 9,269 0.0153% | $6.16 | $57,100 | -11.35% | |
| 2024-09-12 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 16,047 0.0263% | $6.00 | $96,309 | -9.06% | |
| 2024-09-11 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 541,897 0.833% | $6.00 | $3.25M | -12.38% | |
| 2024-07-05 | Sale | Dunn Edmund | Principal Accounting Officer | 1,610 0.0027% | $3.83 | $6,166 | +51.37% | |
| 2024-06-03 | Sale | Dunn Edmund | Principal Accounting Officer | 1,207 0.002% | $4.04 | $4,876 | +38.32% | |
| 2021-06-28 | Yang Rick | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | ||
| 2021-06-28 | Walker Paul Edward | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | ||
| 2021-06-28 | Sonsini Peter W. | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% |
| Warmuth Markus | President & CEO | 618937 0.9504% | $14.67M | 0 | 2 | |
| Janku Filip | Chief Medical Officer | 75026 0.1152% | $1.78M | 0 | 1 | |
| Townson Sharon | Chief Scientific Officer | 67845 0.1042% | $1.61M | 0 | 1 | |
| Champoux Jennifer | Chief Operating Officer | 62371 0.0958% | $1.48M | 0 | 1 | |
| Nickson Philip | Chief Business & Legal Officer | 60845 0.0934% | $1.44M | 0 | 1 | |
| Dunn Edmund | Principal Accounting Officer | 22693 0.0348% | $538,051.03 | 0 | 4 | |
| Leo Chandra P. | director | 10000 0.0154% | $237,100.00 | 1 | 0 | |
| MAKOWER JOSHUA | 10 percent owner | 7692298 11.812% | $182.38M | 1 | 0 | <0.0001% |
| SANDELL SCOTT D | 10 percent owner | 7692298 11.812% | $182.38M | 1 | 0 | <0.0001% |
| BASKETT FOREST | 10 percent owner | 7692298 11.812% | $182.38M | 1 | 0 | <0.0001% |
| Mathers Edward T | 10 percent owner | 7692298 11.812% | $182.38M | 1 | 0 | <0.0001% |
| Walker Paul Edward | 10 percent owner | 7692298 11.812% | $182.38M | 1 | 0 | <0.0001% |
| Sonsini Peter W. | 10 percent owner | 7692298 11.812% | $182.38M | 1 | 0 | <0.0001% |
| Florence Anthony A. Jr. | 10 percent owner | 7692298 11.812% | $182.38M | 1 | 0 | <0.0001% |
| Behbahani Ali | 7692298 11.812% | $182.38M | 1 | 0 | <0.0001% | |
| Landsman Liza | 10 percent owner | 7692298 11.812% | $182.38M | 1 | 0 | <0.0001% |
| Makhzoumi Mohamad | 10 percent owner | 7692298 11.812% | $182.38M | 1 | 0 | <0.0001% |
| Chang Carmen | 10 percent owner | 7692298 11.812% | $182.38M | 1 | 0 | <0.0001% |
| New Enterprise Associates 17, L.P. | director | 7692298 11.812% | $182.38M | 1 | 0 | <0.0001% |
| Yang Rick | 10 percent owner | 7692298 11.812% | $182.38M | 1 | 0 | <0.0001% |
| Cormorant Asset Management, LP | 3202200 4.9172% | $75.92M | 1 | 0 | <0.0001% | |
| Bolzon Bradley J PhD | 2097938 3.2215% | $49.74M | 1 | 0 | <0.0001% | |
| Versant Venture Capital VI, L.P. | 10 percent owner | 1573453 2.4161% | $37.31M | 1 | 6 | <0.0001% |
$831,902,292 | 108 | 9.34% | $1.6B | |
$607,159,124 | 92 | 3.55% | $1.32B | |
$21,345,882 | 83 | 94.45% | $1.4B | |
$1,103,317,478 | 60 | 36.54% | $1.64B | |
$1,376,668 | 53 | 18.46% | $1.89B | |
$613,304,943 | 46 | 11.85% | $1.44B | |
$678,065,999 | 37 | -13.32% | $1.34B | |
$1,603,489 | 30 | 98.90% | $1.7B | |
$104,199,091 | 28 | 16.42% | $1.39B | |
$75,269,735 | 23 | -2.06% | $1.76B | |
Monte Rosa Therapeutics, Inc. (GLUE) | $276,750,010 | 16 | -7.95% | $1.54B |
$154,554,190 | 14 | 29.60% | $1.59B | |
$18,336,420 | 12 | 24.03% | $1.44B | |
$2,859,892 | 10 | 29.21% | $1.78B | |
$94,976,497 | 10 | -10.72% | $1.64B | |
$93,268,646 | 8 | -37.22% | $1.54B | |
$46,235,722 | 6 | -31.77% | $1.45B | |
$103,599,972 | 2 | -36.81% | $1.87B | |
$504,640 | 1 | 16.84% | $1.52B |
| Increased Positions | 67 | +51.54% | 6M | +9.15% |
| Decreased Positions | 53 | -40.77% | 8M | -13.37% |
| New Positions | 30 | New | 3M | New |
| Sold Out Positions | 14 | Sold Out | 4M | Sold Out |
| Total Postitions | 144 | +10.77% | 59M | -4.22% |
| Nea Management Company, Llc | $117,769.00 | 11.83% | 7.69M | 0 | 0% | 2025-09-30 |
| Bvf Inc/Il | $86,657.00 | 8.71% | 5.66M | 0 | 0% | 2025-09-30 |
| Versant Venture Management, Llc | $86,546.00 | 8.7% | 5.65M | 0 | 0% | 2025-09-30 |
| Baker Bros. Advisors Lp | $75,265.00 | 7.56% | 4.92M | 0 | 0% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $70,993.00 | 7.13% | 4.64M | -2M | -26.69% | 2025-09-30 |
| Blackrock, Inc. | $58,410.00 | 5.87% | 3.82M | -31,321 | -0.81% | 2025-09-30 |
| Suvretta Capital Management, Llc | $51,442.00 | 5.17% | 3.36M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $45,761.00 | 4.6% | 2.99M | -151,557 | -4.83% | 2025-09-30 |
| Fmr Llc | $43,056.00 | 4.33% | 2.81M | +524,217 | +22.91% | 2025-09-30 |
| Aisling Capital Management Lp | $22,541.00 | 2.27% | 1.47M | 0 | 0% | 2025-09-30 |